Comparison of tumor response by Response
β
Julien Edeline; Eveline Boucher; Yan Rolland; Elodie VaulΓ©on; Marc Pracht; Chris
π
Article
π
2011
π
John Wiley and Sons
π
English
β 578 KB
## Abstract ## BACKGROUND: A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed